

Carlos A Castaneda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/574370/publications.pdf>

Version: 2024-02-01

44
papers

1,369
citations

516215

16
h-index

360668

35
g-index

50
all docs

50
docs citations

50
times ranked

2717
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy in triple-negative breast cancer: A literature review and new advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 219-236.	0.9	16
2	A biomarker study in Peruvian males with breast cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 926-934.	0.9	1
3	Detection of <i>Helicobacter pylori</i> in gastric cancer tissue through histopathology, immunohistochemistry and real-time reverse transcription-PCR. <i>Future Microbiology</i> , 2020, 15, 1131-1137.	1.0	4
4	ABC4 Consensus: First Latin American Meeting's Assessment, Comments, and Application of Its Recommendations. <i>JCO Global Oncology</i> , 2020, 6, 819-827.	0.8	2
5	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
6	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
7	Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. <i>Cancer Research</i> , 2020, 80, 1893-1901.	0.4	29
8	Role of undifferentiation markers and androgen receptor expression in triple-negative breast cancer. <i>Breast Journal</i> , 2019, 25, 1316-1319.	0.4	3
9	Prevalence of <i>Helicobacter pylori</i> Infection, Its Virulent Genotypes, and Epstein-Barr Virus in Peruvian Patients With Chronic Gastritis and Gastric Cancer. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	12
10	Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1127-1134.	1.2	20
11	Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. <i>Biomarkers in Medicine</i> , 2019, 13, 1481-1491.	0.6	16
12	<i>Helicobacter Pylori</i> Detected in Tap Water of Peruvian Patients with Gastric Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3193-3196.	0.5	6
13	Genetics, tumor features and treatment response of breast cancer in Latinas. <i>Breast Cancer Management</i> , 2018, 7, BMT01.	0.2	2
14	Impact of pathological features of brain metastases in prognosis. <i>Biomarkers in Medicine</i> , 2018, 12, 475-485.	0.6	7
15	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
16	MGMT promoter methylation in Peruvian patients with glioblastoma. <i>Ecancermedicalscience</i> , 2018, 12, 812.	0.6	1
17	Breast cancer subtype and survival among Indigenous American women in Peru. <i>PLoS ONE</i> , 2018, 13, e0201287.	1.1	8
18	Critical review of axillary recurrence in early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 146-152.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Androgen expression & clinicopathological features in male breast cancer. Breast Cancer Management, 2018, 7, BMT07.	0.2	2
20	Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World Journal of Clinical Oncology, 2018, 9, 33-41.	0.9	23
21	Distribution of tumor-infiltrating immune cells in glioblastoma. CNS Oncology, 2018, 7, CNS21.	1.2	42
22	Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clinical and Translational Oncology, 2017, 19, 1478-1488.	1.2	46
23	Glioblastoma of pineal region: report of four cases and literature review. CNS Oncology, 2017, 6, 251-259.	1.2	11
24	The implementation of the Plan Esperanza and response to the impACT Review. Lancet Oncology, The, 2017, 18, e595-e606.	5.1	29
25	Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer. Molecular Genetics & Genomic Medicine, 2017, 5, 481-494.	0.6	14
26	Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology, 2016, 23, 2242-2248.	0.7	85
27	Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World Journal of Clinical Oncology, 2016, 7, 387.	0.9	42
28	Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer. CNS Oncology, 2015, 4, 137-145.	1.2	8
29	Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. Cancer Research, 2015, 75, 2243-2253.	0.4	62
30	Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a Latina population. Breast Cancer Management, 2015, 4, 295-302.	0.2	1
31	Glioblastoma: análisis molecular y sus implicancias clínicas. Revista Peruana De Medicina De Experimental Y Salud Publica, 2015, 32, 316.	0.1	5
32	Resección microquirúrgica de glioblastoma guiada con fluorescencia intraoperatoria: evaluación retrospectiva. Revista Peruana De Medicina De Experimental Y Salud Publica, 2015, 32, 471.	0.1	4
33	Amebiasis del sistema nervioso central: reporte de seis casos en el Perú. Revista Peruana De Medicina De Experimental Y Salud Publica, 2015, 32, 591.	0.1	2
34	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 142-148.	0.6	18
35	Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 149-156.	0.6	10
36	The present and future of gene profiling in breast cancer. Cancer and Metastasis Reviews, 2012, 31, 41-46.	2.7	15

#	ARTICLE	IF	CITATIONS
37	Behaviour of breast cancer molecular subtypes through tumour progression. <i>Clinical and Translational Oncology</i> , 2012, 14, 481-485.	1.2	15
38	Implication of miRNA in the diagnosis and treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1265-1275.	1.1	20
39	Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 455-463.	1.1	18
40	Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 109-115.	0.6	14
41	The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 751-759.	2.7	146
42	Pazopanib: an antiangiogenic drug in perspective. <i>Future Oncology</i> , 2009, 5, 1335-1348.	1.1	22
43	Combined lapatinib and paclitaxel in HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 308-309.	12.5	10
44	Prolonged Disease Control in a Patient With Anthracycline- and Taxane-Resistant Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, E1-E3.	1.1	1